Validation of postinduction Curie scores in high-risk neuroblastoma.

10031 Background: A semi-quantitative MIBG scoring method (Curie scoring, CS) has been previously examined in the Children’s Oncology Group (COG) high-risk neuroblastoma trial, COG A3973, with a post-induction CS >2 associated with poor event-free (EFS) and overall survival (OS). We now examine the impact of Curie scoring in an independent data set, the SIOPEN-HR-NBL1 (SIOPEN-NB) high-risk study. Methods: MIBG scans from patients with MIBG avid, INSS stage 4 neuroblastoma enrolled on SIOPEN-NB were evaluated at diagnosis (n=345) and post-induction (n=330). Scans were evaluated in 10 different anatomic regions by 2 reviewers, including 9 skeletal and 1 soft issue region, with each region scored 0-3 based upon disease extent, and a cumulative consensus score generated. Optimal cut-points at diagnosis (Dx) and post-induction were determined using the Youden index, with outcomes determined. Curie scores from patients enrolled on COG A3973 at diagnosis (n= 280) and post-induction (n= 237) were used for compari...